Skip to content

Anlotinib

Tasigna (anlotinib) is a small molecule pharmaceutical. Anlotinib was first approved as Tasigna on 2007-11-19. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1.
Trade Name Tasigna
Common Name Anlotinib
Indication bcr-abl positive chronic myelogenous leukemia
Drug Class Tyrosine kinase inhibitors
Anlotinib
Get full access now